In recent studies involving patients treated with anti-programmed cell death protein 1/programmed death-ligand 1 immunotherapy for non-small-cell lung cancer and small-cell lung cancer, it was reported that patients with high post-treatment NLRs (≥5) had significantly shorter PFS [37,38]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.